NTNozomu Takata

Nozomu Takata

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nozomu Takata has a total of 162 co-authors. Here are the top co-authors by number of shared publications:

  • Mototsugu Eiraku

    Institute for Life and Medical Sciences, Kyoto University, Sakyo-ku

    9 shared publications
  • Yoshiki Sasai

    Laboratory for Organogenesis and Neurogenesis, RIKEN Center for Developmental Biology, 2-2-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan

    9 shared publications
  • Eriko Sakakura

    Laboratory for in vitro Histogenesis, RIKEN Center for Developmental Biology, 2-2-3 Minatojima-minamimachi, Chuo-ku, Kobe, Hyogo, 650-0047, Japan

    6 shared publications
  • Bunsho Itoh

    Department of Oncogene Research, Research Institute for Microbial Diseases, Osaka University, 3-1 Yamadaoka, Suita Osaka 565-0871, Japan

    3 shared publications
  • Guillermo Oliver

    Center for Vascular and Developmental Biology, Feinberg Cardiovascular and Renal Research Institute, Feinberg School of Medicine, Northwestern University, Chicago, USA

    3 shared publications
  • Oren Becher

    Department of Pediatrics, Kravis Children's Hospital, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

    3 shared publications

Latest Publications

  • Precise length and charge segmentation of billion-dalton supramolecular polymers

    by Michael D. Dore, Madison Strong, Simon A. Egner, Hiroaki Sai, Kyle Gray, Nozomu Takata, Alexie Nyambi, Zhiwei Li, Liam C. Palmer, Samuel I. Stupp

    Supramolecular polymers with precise micrometer-scale segments of opposite charge are challenging to synthesize as discrete assemblies in water. These systems could be used to pattern charged surfaces, interact with the membranes of cells, or form hierarchical structures. We report a living polymerization of fibrillar peptide assemblies with a central positively charged segment flanked by negative ones that can have a collective molar mass on the order of billions of daltons. The self-capping supramolecular polymerization required an untwisted β sheet core persisting along the entire length of the assembly as well as dormant ends in the absence of a monomer source. The positive domains of the segmented structures were anchored to the membranes of neurons, leaving the connected negative segments in a highly dynamic state near the cells through charge repulsion. The segmented architecture generated extensive neurite growth and synaptic activity.


  • Design of Neuronal Supramolecular Scaffolds Integrating Cell Signaling and Electrical Conductivity

    by Anna Metlushko, Nicholas A. Sather, Timmy Fyrner, Nozomu Takata, Yaroslav Vorobyov, Radoslav Z. Pavlović, Dina Simkin, Oscar A. Carballo-Molina, Cassandre Jamroz, Evangelos Kiskinis, et al.

    Scaffolds with neuronal bioactivity are important to promote repair of the central and peripheral nervous systems, in vitro neuronal differentiation and maturation for transplantation, and the integration of electronic devices with neural tissues, among others. Previous work in this area includes the incorporation of growth factors, stem cells, or conducting polymers into scaffolds, but efficacy has been limited. We report here on an extrusion-printable bioactive scaffold that incorporates laminin-mimetic peptide amphiphile (PA) supramolecular filaments, a conducting polymer, and the anionic polysaccharide known as gellan gum. The conducting polymer used was poly(3,4-ethylenedioxythiophene) (PEDOT) with dual functionalization by design with alkoxysulfonates and hydroxyl groups. Hydroxyl groups hydrogen bonded with the polysaccharide, which enhanced both the conductivity and biocompatibility of the scaffolds by preventing the PEDOT from leaching out into cell media. When combined with PA filaments, the scaffold synergistically enhanced neuronal maturation and electrophysiological function in cultures of mouse and human cells. Interestingly, the conducting polymer was found to scavenge reactive oxygen species (ROS) and increase neuronal maturation potentially through cAMP response element-binding protein (CREB) pathways. Furthermore, extrusion printing the scaffold resulted in alignment of the bioactive supramolecular filaments and the cultured neurons, a key feature of natural neural tissues. Our findings suggest this biomaterial scaffold shows potential to promote neural bioactivity in a wide variety of regenerative medicine and bioelectronic applications.


  • Top Cited Papers

    Injury and therapy in a human spinal cord organoid

    by Nozomu Takata, Zhiwei Li, Anna Metlushko, Feng Chen, Nicholas A. Sather, Xinyi Lin, Matthew J. Schipma, Oscar A. Carballo-Molina, Cassandre Jamroz, Madison E. Strong, et al.

    Damage to the spinal cord can lead to irreversible paralysis and loss of sensory function, but translation of preclinical therapies remains elusive. We recently showed that bioactive supramolecular assemblies of peptide amphiphiles can reverse paralysis in an acute mouse model following severe spinal cord injury (SCI). Here we report the development of two human spinal cord organoid injury models to simulate SCI in vitro, a laceration of the organoid with a scalpel and a compressive contusion commonly used in preclinical models, both resulting in immediate neuronal death and the formation of glial scar-like tissue. Treatment of the injured organoids with the preclinical therapy suppressed the scar-like tissue and promoted significant axonal regeneration, as observed previously in vivo. With the inclusion of microglia into the spinal cord organoids, we demonstrate that the supramolecular nanomaterial reduced pro-inflammatory factors commonly associated with injury. The human spinal cord organoid models developed here could accelerate the discovery of therapies to treat SCI and possibly damage of other central nervous system tissues owing to trauma or disease.


  • Open Access

    Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models

    by Yusuke Tomita, Gabrielle Link, Yi Ge, Emma R. H. Gold, Anna Racanelli, Herminio Joey Cardona, Megan Romero, Samantha Gadd, Jun Watanabe, Eita Uchida, et al.

    Background: Diffuse midline glioma (DMG) is an incurable brain cancer without a single FDA-approved drug that prolongs survival. CDK4/6 inhibitors have been evaluated in children with DMG with limited efficacy. Since MAPK pathway activation is upstream of cell proliferation, we hypothesized that MEK inhibitors may increase the anti-tumor effects of CDK4/6 inhibitors. Here, we evaluated the efficacy of the CDK4/6 inhibitor ribociclib and the MEK inhibitor trametinib in human and murine DMG models to investigate combinational effects. Methods: We conducted in vitro and in vivo assays using DMG cell lines from human patient-derived xenografts (PDX) and genetically engineered mouse (GEM) models. In vitro, we assessed synergy across human DMG lines. In vivo , we evaluated therapeutic effects with histological examinations, survival analysis, pharmacokinetic measurements, and RNA-sequencing analysis. Results: In vitro , ribociclib and trametinib had variable synergistic effects against human DMG cell lines. In vivo , a five-day treatment with combination therapy in the GEM DMG model significantly decreased cell proliferation and increased apoptosis compared with the vehicle, with trametinib having mostly cytotoxic effects and ribociclib having primarily cytostatic effects. In addition, a 21-day treatment with combination therapy significantly prolonged mice survival compared with the vehicle in the GEM DMG model (median survival: 112 days vs. 71.5 days, log rank test p = 0.0195). In an orthotopic PDX model, combination therapy did not prolong mice survival compared with vehicle, ribociclib, and trametinib. LC/MS analysis showed adequate drug delivery across the blood-brain-barrier (BBB) into tumor tissue in both GEM and PDX models. Transcriptomic analysis in the GEM model suggests that combination therapy inhibited the MAPK pathway and inflammation. Conclusions: Combination therapy with ribociclib and trametinib significantly prolonged survival in the GEM model but not in the PDX model, highlighting the importance of testing novel therapies in diverse models.


  • Open Access

    Effects of Combination Therapy of a CDK4/6 and MEK Inhibitor in Diffuse Midline Glioma Preclinical Models

    by Yusuke Tomita, Gabrielle Link, Yi Ge, Emma R.H. Gold, Herminio J. Cardona, Megan M. Romero, Samantha Gadd, Jun Watanabe, Eita Uchida, Rintaro Hashizume, et al.

    Background: Diffuse midline glioma (DMG) is an incurable brain cancer without a single FDA-approved drug that prolongs survival. CDK4/6 inhibitors have been evaluated in children with DMG with limited efficacy. Since MAPK pathway activation is upstream of cell proliferation, we hypothesized that MEK inhibitors may increase the anti-tumor effects of CDK4/6 inhibitors. Here, we evaluated the efficacy of the CDK4/6 inhibitor ribociclib and the MEK inhibitor trametinib in human and murine DMG models to investigate combinational effects. Methods: We conducted in vitro and in vivo assays using DMG cell lines from human patient-derived xenografts (PDX) and murine genetically engineered models (GEM). In vitro, we assessed synergy across human DMG lines. In vivo , we evaluated therapeutic effects with histological examinations, survival analysis, pharmacokinetic measurements, and RNA-sequencing analysis. Results: In vitro , ribociclib and trametinib had variable synergistic effects against human DMG cell lines. In vivo , a five-day treatment with combination therapy in the GEM DMG model significantly decreased cell proliferation and increased apoptosis compared with the vehicle, with trametinib having mostly cytotoxic effects and ribociclib having primarily cytostatic effects. In addition, a 21-day treatment with combination therapy significantly prolonged mice survival compared with the vehicle in the GEM DMG model (median survival: 112 days vs. 71.5 days, log rank test p=0.0195). In an orthotopic PDX model, combination therapy did not prolong mice survival compared with vehicle, ribociclib, and trametinib. LC/MS analysis showed adequate drug delivery across the blood-brain-barrier (BBB) into tumor tissue in both GEM and PDX models. Transcriptomic analysis in the GEM model suggests that combination therapy inhibited the MAPK pathway and inflammation. Conclusions: Combination therapy with ribociclib and trametinib significantly prolonged survival in the GEM model but not in the PDX model, highlighting the importance of testing novel therapies in diverse models. Key Points: Combination therapy had cytotoxic and cytostatic effects in vivo in the GEM model. Combination therapy had variable synergy in vitro in human DIPG models. Combination therapy significantly prolonged mice survival compared with the vehicle in the GEM model. Combination therapy did not prolong survival in the PDX model. Transcriptional analysis suggests that the combination modulated inflammation in the GEM model. This work highlights the importance of testing novel therapies in diverse models. Importance of the Study: DMG is an incurable brain cancer without a single FDA-approved drug that prolongs survival. CDK4/6 inhibitors have been evaluated in children with DMG with limited efficacy. As MAPK pathway activation is known to be upstream of cell proliferation, we hypothesize that combination therapy will have additive effects relative to monotherapy. In this study, we evaluated the efficacy of the CDK4/6 inhibitor ribociclib and the MEK inhibitor trametinib in GEM and PDX DMG models. In vitro , the inhibitor combination demonstrated variable synergy in DMG human cell-lines, but in vivo , it had limited efficacy in a PDX orthotopic model. In the GEM model, the combination prolonged survival compared with the vehicle and with single agents. PK studies showed similar drug levels in tumor tissue between the GEM and PDX models. Transcriptomic analysis in the GEM suggests that the drug combination significantly inhibited inflammation. These results highlight the importance of testing therapies in diverse models and suggest that this combination may be an effective therapy in patients with DMG.


  • Open Access

    BET bromodomain inhibition potentiates radiosensitivity in models of H3K27-altered diffuse midline glioma

    by Jun Watanabe, Matthew R. Clutter, Michael J. Gullette, Takahiro Sasaki, Eita Uchida, Savneet Kaur, Yan Mo, Kouki Abe, Yukitomo Ishi, Nozomu Takata, et al.

    Diffuse midline glioma (DMG) H3K27-altered is one of the most malignant childhood cancers. Radiation therapy remains the only effective treatment yet provides a 5-year survival rate of only 1%. Several clinical trials have attempted to enhance radiation antitumor activity using radiosensitizing agents, although none have been successful. Given this, there is a critical need for identifying effective therapeutics to enhance radiation sensitivity for the treatment of DMG. Using high-throughput radiosensitivity screening, we identified bromo- and extraterminal domain (BET) protein inhibitors as potent radiosensitizers in DMG cells. Genetic and pharmacologic inhibition of BET bromodomain activity reduced DMG cell proliferation and enhanced radiation-induced DNA damage by inhibiting DNA repair pathways. RNA-Seq and the CUT&RUN (cleavage under targets and release using nuclease) analysis showed that BET bromodomain inhibitors regulated the expression of DNA repair genes mediated by H3K27 acetylation at enhancers. BET bromodomain inhibitors enhanced DMG radiation response in patient-derived xenografts as well as genetically engineered mouse models. Together, our results highlight BET bromodomain inhibitors as potential radiosensitizer and provide a rationale for developing combination therapy with radiation for the treatment of DMG.


  • Open Access

    Lactate-dependent transcriptional regulation controls mammalian eye morphogenesis

    by Nozomu Takata, Jason M. Miska, Marc A. Morgan, Priyam Patel, Leah K. Billingham, Neha Joshi, Matthew J. Schipma, Zachary J. Dumar, Nikita R. Joshi, Alexander V. Misharin, et al.

    Mammalian retinal metabolism favors aerobic glycolysis. However, the role of glycolytic metabolism in retinal morphogenesis remains unknown. We report that aerobic glycolysis is necessary for the early stages of retinal development. Taking advantage of an unbiased approach that combines the use of eye organoids and single-cell RNA sequencing, we identify specific glucose transporters and glycolytic genes in retinal progenitors. Next, we determine that the optic vesicle territory of mouse embryos displays elevated levels of glycolytic activity. At the functional level, we show that removal of Glucose transporter 1 and Lactate dehydrogenase A gene activity from developing retinal progenitors arrests eye morphogenesis. Surprisingly, we uncover that lactate-mediated upregulation of key eye-field transcription factors is controlled by the epigenetic modification of histone H3 acetylation through histone deacetylase activity. Our results identify an unexpected bioenergetic independent role of lactate as a signaling molecule necessary for mammalian eye morphogenesis.


  • Open Access

    Optogenetic control of apical constriction induces synthetic morphogenesis in mammalian tissues

    by Guillermo Martínez-Ara, Núria Taberner, Mami Takayama, Elissavet Sandaltzopoulou, Casandra E. Villava, Miquel Bosch-Padrós, Nozomu Takata, Xavier Trepat, Mototsugu Eiraku, Miki Ebisuya

    The emerging field of synthetic developmental biology proposes bottom-up approaches to examine the contribution of each cellular process to complex morphogenesis. However, the shortage of tools to manipulate three-dimensional (3D) shapes of mammalian tissues hinders the progress of the field. Here we report the development of OptoShroom3, an optogenetic tool that achieves fast spatiotemporal control of apical constriction in mammalian epithelia. Activation of OptoShroom3 through illumination in an epithelial Madin-Darby Canine Kidney (MDCK) cell sheet reduces the apical surface of the stimulated cells and causes displacements in the adjacent regions. Light-induced apical constriction provokes the folding of epithelial cell colonies on soft gels. Its application to murine and human neural organoids leads to thickening of neuroepithelia, apical lumen reduction in optic vesicles, and flattening in neuroectodermal tissues. These results show that spatiotemporal control of apical constriction can trigger several types of 3D deformation depending on the initial tissue context.


  • Open Access

    A reflection of life – my tale of microdiversity, equity and inclusion in cell biology (and beyond)

    by Nozomu Takata

    Just as an organism depends on a multitude of different factors to function, from biochemical to environmental, a society depends on various dimensions of diversity to survive, but even more so to thrive. This concept was not lost on me when I moved to the USA. I started my scientific journey in my home country of Japan, where I trained in various disciplines. This transdisciplinary experience enabled me to grow and succeed as a researcher in cell and developmental biology. As I reframed my cross-cultural and cross-disciplinary experiences, I learned to incorporate an array of diverse fields into my daily life and research philosophy. Japan is a relatively homogenous society with a tradition of following established protocols and rules, thereby rarely changing. By comparison, the USA is a confluence of different backgrounds, experiences and perspectives. The change in exposure to diversity not only helped me to expand my social life but also my ‘science life’. This essay is a testament to the growth in my appreciation for diversity at all levels; I will share my thoughts and experiences about the parallels that can be drawn between cellular diversity and its innate model for societal diversity.Increasing equity, diversity and inclusion is crucial for academic science and education. A diverse environment (including diversity in race, ethnicity, gender, religion, sexual orientation and socioeconomic status) is a true reflection of what life in any typical society should be (Hollins and Govan, 2015). Diversity is what makes us a rich community – by recognizing our differences. Embracing diversity is important because it gives us a chance to validate who we are individually and how we are different. Yet, we are equal, and we should keep things equal, because diversity should not limit someone's access to opportunity; in fact, it may even fuel it. Therefore, diversity in academic society enables the reaction and combination of unique ideas when equity and inclusion support all those activities. As a cell biologist, I am proud that the scientific community continues to make strides to be more diverse and to be functionally united. Overall, I am committed to advancing equity, diversity and inclusion by treating everyone respectfully and equally so that everyone can reach the full potential of academic society. And I believe having diversity provides the community with a scientifically active environment and innovation (Fig. 1). I could not be more proud to take a leadership role to further diversity.Like our society, a living organism uses complex and sophisticated systems that are diversified and that have been acquired evolutionarily to appropriately process information from both the inside and outside. Such systems are the key to organogenesis, regeneration and homeostasis, and any abnormality in the system or failure of the related molecular machinery can lead to congenital abnormalities and serious diseases. Cells are the building blocks of our bodies, and yet each cell type has its own specific role. The technology available for working with cells has enabled a reductive approach to understanding the whole by breaking down the complex components into their parts and examining them. As a result, it becomes clear that these tiny cells are equipped with amazingly complex mechanisms for responding to the outside world and for intracellular processing. Furthermore, by integrating these functions at the tissue and organ levels, advanced and diverse functions that could not be attained on a cellular level can be achieved. I strongly believe that cell biology will continue to play a variety of roles in bridging between molecules and organisms. As our knowledge advances, more challenges must be addressed to support the merging of scientific disciplines and the act of consciously being more open-minded and inclusive. These efforts will bring us a new interpretation of pathology, breaking away from the classical interpretation.I was born and raised in a rural town in Tokushima prefecture, Japan, called Iwazu, which had a population of ∼10,000. My grandparents, parents and I lived together in the same house as an extended family. I grew up surrounded by an abundance of nature and being attracted to, and learning from, many living creatures. I decided to pursue an academic career, becoming the first person in our family and relatives' history who chose to go to college. It took time for me to learn the concept of ‘microdiversity’. I did not encounter the word ‘cell’ until much later, when I entered the University of Nagoya, where with great mentoring by Dr Yasunori Machida, I learned about diversity of cell types, including well-coordinated plant cells, and the explicit diversity of function driven by varieties of cell organelles and molecules, including genetic material. This initial study of plant genetics inspired me to learn quite a few lessons from the secret communication of molecular and cellular diversity under the microscope.The diversity of gene families was my PhD story and first-ever published contribution to scientific society (Itoh et al., 2005; Takata et al., 2009). To gain more insights into biology, I took a unique approach with C. elegans, a type of nematode model and an evolutionarily old animal, in the lab of Dr Masato Okada. One of the reasons that the model struck me was that only ∼1000 somatic cells elegantly coordinate diverse functions during the life cycle (Sternberg and Horvitz, 1982), and it also made me realize the genetic diversity in this ancestral species. Furthermore, this simple animal has ∼20,000 genes, and this set of genes is sufficient to exert the diversity of roles of all gene categories, highlighting both the similarities and differences between the genetic material of different organisms. I learned particularly about the evolutionary role of a proto-oncogene family. Characterization of the genes...